3. 3
OUR Vision
To be the world leader
in precision biology
replacing animal testing
with accurate,
human relevant
technologies
4. 4
$26m DARPA contract with the Massachusetts Institute of Technology
a Human-on-a-Chip?
5. 5
Benefits
Intellectual Property
IP Pipeline
CN Bio secured exclusive rights to
commercialise all IP arising from the
MIT-led DARPA consortium’s research
to develop a human body-on-a-chip.
Team
Recruiting new skills
DARPA grant enabled CN Bio to hire
new team members bringing
specialist biology and engineering
skills into our business.
Expert Collaborators
MIT Professor Linda Griffith
Professor of Biological & Mechanical
engineering. Lead PI on $26M DARPA
contract. US National Academy of
Engineers. Recipient of MacArthur
“Genius” Fellowship.
6. 6
“Ensuring that Britain remains
attractive for inward investment
will surely help more companies like
ours access the funding needed for
growth”
E. Sceats
9. 9
“As small companies endeavour to
become large and internationally
successful businesses
understanding the challenges and
trade-offs these businesses face
will be crucial for developing
policies that will nurture home-
grown talent”
E. Sceats
10. 10
Ecosystem
TWO global Big Pharma companies
(AZ, GSK) headquartered in UK
Thriving biotech sector from large,
international players (e.g. Shire) to
university spin-outs
World-class medical devices sector
employing >50,000 staff
UK life sciences sector employs
>233,000 people, generating £64bn
revenue each year
#1 destination for
foreign direct
investment in
Europe
11. 11
“It will be exciting to see how
implementation of Sir John Bell’s
recommendations can be a catalyst
for growth, both for our company
and our country”
E. Sceats